$1.19
4.03% yesterday
Nasdaq, Nov 15, 10:00 pm CET
ISIN
US4277461020
Symbol
HRTX
Sector
Industry

Heron Therapeutics Inc Stock price

$1.19
-0.61 33.89% 1M
-1.81 60.33% 6M
-0.51 30.00% YTD
+0.33 38.37% 1Y
-9.74 89.11% 3Y
-20.39 94.49% 5Y
-6.78 85.07% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-0.05 4.03%
ISIN
US4277461020
Symbol
HRTX
Sector
Industry

Key metrics

Market capitalization $180.48m
Enterprise Value $287.84m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.09
P/S ratio (TTM) P/S ratio 1.31
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 12.13%
Revenue (TTM) Revenue $137.74m
EBIT (operating result TTM) EBIT $-25.92m
Free Cash Flow (TTM) Free Cash Flow $-9.61m
Cash position $70.89m
EPS (TTM) EPS $-0.18
P/E forward negative
P/S forward 1.33
EV/Sales forward 2.10
Short interest 24.56%
Show more

Is Heron Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Heron Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Heron Therapeutics Inc forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a Heron Therapeutics Inc forecast:

Buy
100%

Financial data from Heron Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
138 138
12% 12%
100%
- Direct Costs 38 38
44% 44%
28%
99 99
81% 81%
72%
- Selling and Administrative Expenses 98 98
16% 16%
71%
- Research and Development Expense 24 24
56% 56%
18%
-23 -23
80% 80%
-17%
- Depreciation and Amortization 2.63 2.63
12% 12%
2%
EBIT (Operating Income) EBIT -26 -26
79% 79%
-19%
Net Profit -28 -28
77% 77%
-20%

In millions USD.

Don't miss a Thing! We will send you all news about Heron Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Heron Therapeutics Inc Stock News

Neutral
Seeking Alpha
3 days ago
Heron Therapeutics, Inc. (NASDAQ:HRTX ) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Melissa Jarel - Executive Director Craig Collard - Chief Executive Officer Ira Duarte - Executive Vice President & Chief Financial Officer William Forbes - Executive Vice President & Chief Development Officer Conference Call Participants Carl Byrnes - Northland Capital Mark...
Neutral
PRNewsWire
4 days ago
Reported positive YTD 2024 Adjusted EBITDA of $1.4 million Company expects Q4 2024 Net Revenue in the range of $37 million - $43 million ZYNRELEF® (bupivacaine and meloxicam) extended-release solution Vial Access Needle ("VAN") approved in September and on track for Q4 2024 launch CMS Final Rule Non-Opioid Policy for Pain Relief includes ZYNRELEF as a qualifying product for separate payment in ...
Neutral
PRNewsWire
11 days ago
SAN DIEGO , Nov. 4, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, announced today the appointment of Michael Kaseta to its Board of Directors. Mr. Kaseta has an extensive background spanning corporate finance, business strategy, and the commercialization of biopharma products in large pharmaceutical companies and small biotech companies.
More Heron Therapeutics Inc News

Company Profile

Heron Therapeutics, Inc. is a biotechnology company, which engages in the development of pharmaceutical products for patients suffering from cancer. Its products portfolio include SUSTOL, Cinvanti, HTX-011, and HTX-034. The company was founded in February 1983 and is headquartered in Redwood City, CA.

Head office United States
CEO Craig Collard
Employees 126
Founded 1983
Website www.herontx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today